palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options

Clicks: 189
ID: 208249
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #138 of 171 articles by views in jurnal tam

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Laurie Elit,1,2 Hal Hirte21Department of Obstetrics and Gynecology, McMaster University, Hamilton, Ontario, Canada; 2Department of Oncology, McMaster University, Hamilton, Ontario, CanadaObjectives: To review the available systemic treatments for women with recurrent ovarian cancer.Methods: A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews.Results: We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer. Clearly, platinum-based combination systemic therapy shows a prolonged progression-free interval compared with single-agent chemotherapy with a low toxicity profile. No clear superior management strategy exists for platinum-resistant/refractory disease. Novel targeted antiangiogenic agents (eg, bevacizumab), angiopoeitin inhibitors (eg, AMG 386), and poly ADP ribose polymerase inhibitors (eg, olaparib) are reviewed.Conclusion: Although combination platinum-based chemotherapy has shown benefits for women with platinum-sensitive recurrent ovarian cancer, the optimal treatment strategy for those with platinum-resistant or platinum-refractory disease is not clear. Molecular and genetic targeted therapies may provide opportunities for those women with tumor profiles that show sensitivity for specific agents.Keywords: ovarian cancer, systemic therapy, biologic agents
Reference Key
l2013oncotargetspalliative Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elit L, Hirte H
Are you one of these authors? Claim your profile
Journal jurnal tam
Year 2013
DOI
DOI not found
URL
http://www.dovepress.com/palliative-systemic-therapy-for-women-with-recurrent-epithelial-ovaria-a12306
Keywords
neoplasms Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.